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Abstract 
Background: Deep brain stimulation (DBS) is an effective therapy in advanced 
Parkinson’s disease (PD), improving motor symptoms, motor complications and quality 
of life. However, adverse psychiatric outcomes have been reported by several authors, 
albeit variably and in an unstandardized fashion. We aimed to summarize the published 
evidence on the outcomes of anxiety and depressive symptoms in PD patients following 
DBS, through systematic review and meta-analysis. 
Methods: Pubmed was searched until May 2012 to identify studies that assessed anxiety 
and depressive symptoms in PD patients who underwent bilateral DBS of the 
subthalamic nucleus (STN) or globus pallidus internus (GPi). Random effects meta-
analyses were conducted for groups of at least three studies that were homogeneous 
regarding the design and the instruments used. 
Results: Depression and anxiety improvement is apparent after DBS, more pronounced 
in the short-term, an effect that seems to wane in later assessments. Concerning 
depression, STN-DBS shows superiority against medical treatment, but not when 
compared to eligible for surgery control groups. The opposite is apparent for anxiety, as 
results favor medical treatment over STN-DBS, and STN-DBS over eligible for surgery 
control group. Superiority of one target over the other is not evident from the results, 
but data slightly favors GPi for both outcomes. 
Conclusions: No clear conclusion can be drawn from this meta-analysis, with the 
possible exception of depression improvement at short-term following STN-DBS, 
although with significant heterogeneity of results. Efforts should be carried out to 
standardize assessment procedures for depression and anxiety in PD patients 
undergoing DBS.  
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Introduction: 
Parkinson’s disease (PD) is a frequent, disabling neurodegenerative condition 
characterized by motor and non-motor symptoms, including cognitive and behavioral1. 
Deep brain stimulation (DBS) has proved effective in advanced PD, as motor 
symptoms, fluctuations, disability and quality of life improve in patients carefully 
selected for the procedure2-4. Recently, the efficacy of DBS has been also demonstrated 
in PD with early motor complications5, suggesting that the universe of potential surgical 
candidates is wider than previously established. However, significant concerns have 
been raised about potential cognitive and psychiatric adverse effects in PD patients 
following DBS, and some data even suggested that consequences might vary according 
to the chosen target, namely the subthalamic nucleus (STN) or the globus pallidus 
internus (GPi)6-8. On the other hand, several studies found no significant adverse 
psychiatric outcomes following DBS in PD9-11. This issue remains incompletely 
clarified, as several different assessment methods have been used, and results have been 
reported under diverse formulas. Data have been reviewed systematically in two 
previous publications concerning psychiatric outcomes in patients undergoing bilateral 
DBS, but one study published in 2006 was limited to patients having STN-DBS12, while 
the other, published in 2007, jointly analyzed results in several pathologies including 
PD13; in addition, several other studies in PD have been published since then, thus 
justifying re-appraisal of findings. We aimed at systematically reviewing the literature 
and summarizing the evidence by meta-analysis, in order to establish state of the art 
knowledge concerning anxiety and depression following DBS in PD. 
 
 
Methods: 
PubMed was searched from inception until May 2012, using the search expression 
“("deep brain stimulation" OR "subthalamic stimulation" OR (stimulation AND 
(“subthalamic nucleus” OR “globus pallidus”))) AND (parkinson disease OR 
parkinson’s disease)”, to identify studies that assessed anxiety and depressive symptoms 
in PD patients who underwent bilateral DBS. 
A total of 3276 references were screened by one of three reviewers (MIC, AM, AO), 
following the same exclusion criteria defined a priori, as follows: 1) language other than 
English, Portuguese and Spanish; 2) non-human data; 3) disorders other than PD; 4) 
studies not concerning DBS; 5) studies not conveying original data (reviews, systematic 
reviews, meta-analysis, book chapters, letters to the editor with no original data); 6) case 
reports; and 7) reports with no data on the outcomes of interest, namely: 7.1) no clinical 
outcome at all (e.g. image methods for target location); 7.2) clinical outcome other than 
psychiatric; 7.3) psychiatric outcome not objectively assessed by psychometric 
instrument. References were then restricted to those reporting on the most relevant DBS 
targets in PD (STN and GPi), and depression or anxiety only. In addition, study design 
details were used to exclude studies not enrolling participants consecutively or 
randomly selected. Duplicate references were eliminated by comparing titles, authors, 
centers and sample details, and a total of 63 reports3,10,14-74 were considered for the 
systematic review. The systematic review flow-chart is presented as appendix 1. 
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Quantitative data on depression and anxiety were collected from the eligible studies 
along with DBS target and follow-up time. Five aspects were considered in order to 
group and analyze data: 1) Main outcome: depression or anxiety; 2) DBS target: STN 
and GPi were individually considered, so studies containing indiscriminate information 
on both targets3,72 have not been analyzed; 3) Follow-up time: three main periods were 
considered: up to 6 months after surgery (short-term follow-up); between 6 months and 
3 years (mid-term follow-up); and more than 3 years (long-term follow-up); within each 
defined time period we selected the data referring to the longest follow-up for analysis, 
whenever data was available for different moments after the intervention; 4) Assessment 
scale(s) employed; 5) Study design: two main types of information were sought: the 
change of variables of interest with the exposure to the procedure (follow-up studies 
with pre- and post-operative data) and the difference between groups concerning the 
response to DBS (studies with different types of comparators). DBS versus controls and 
STN-DBS versus GPi-DBS were considered comparisons of interest, so in studies with 
other comparators, only the information concerning the DBS group was collected. “On” 
state evaluation was considered in studies reporting “on” versus “off” state comparison. 
In partial duplicates with patients overlapping but with different assessment scales35,49, 
follow-up time16,27 or comparison groups73, a selection of relevant data was performed 
for each one, and only specific duplicated information was excluded. A total of 63 
studies assessing depression and/or anxiety following DBS (STN or GPi) in consecutive 
samples of PD patients were selected for analysis. 
Forest-plots were used to summarize the findings from all eligible studies and random 
effects meta-analysis (DerSimonian and Laird method) was performed for groups of at 
least three comparable studies. The I2 statistic was used to quantify heterogeneity. 
Original data concerning different strata from the same studies were assumed as 
different samples, strata being defined by age43, single or multiple recording 
electrodes40, and center (in one collaborative study)73. The pre to postoperative variation 
was calculated from “postop score – preop score”. Differences between STN-DBS and 
the comparison groups were calculated by “STN score – comparator score”. The effect 
size (ES) and corresponding 95% confidence interval (CI) were extracted whenever 
provided in the original reports or computed using the published data considering 
matched and independent samples, respectively (adopted formulas detailed in appendix 
2). Test-retest coefficients have been collected for the several psychometric 
instruments75-86. 
 
 
Results: 
Nearly all studies (n=62, 98.4%) provided data on depression, and 24 (38.1%) on 
anxiety assessment scales. STN-DBS was performed in 60 studies (95.2%) and GPi-
DBS in 9 (14.3%); the overlap between target groups corresponds to STN versus GPi 
comparison studies. Two additional reports3,72 that did not discriminate data by target 
were not considered in our analysis. From the remaining 61 references, short-term 
evaluation was performed in 37 (60.7%), mid-term in 36 (59.0%) and long-term in 5 
(8.2%). Data on pre- to postop variation was available in 57 (93.4%) reports and 16 
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(26.2%) presented STN-DBS versus different comparison groups: the comparators were 
groups of patients submitted to GPi-DBS (4 studies, 25%), eligible for surgery (EFS) (6 
studies, 37.5%) and medical treatment (MT) (7 studies, 43.8%). Information on target, 
study design, assessment scales and follow-up time in each individual study is detailed 
in appendix 2. Ten studies presented non-comparable information, so data presented in 
a quantitative and comparable way from the remaining 52 studies were analyzed 
henceforward. 
 
1) Depression: 
a) Pre – postop variation: 
i) STN-DBS (figures 1 and 2): 
(1) Short-term follow-up: meta-analysis was performed on Beck Depression 
Inventory (BDI), Hamilton Depression Rating Scale (HDRS) and 
Montgomery-Åsberg Depression Rating Scale (MADRS) data. Summary 
effect size (ES) regarding BDI samples pointed to improvement (-3.05, 
I2=68.8%). Slight improvement occurred in HDRS group (ES=-0.286, 
I2=70.5%) and MADRS group (ES=-0.763, I2=0%). All the remaining 
scales showed improvement. 
(2) Mid-term follow-up: meta-analysis was performed on BDI and MADRS 
data only, with summary ES showing very slight improvement, along 
with high heterogeneity of the results: -0.37 (I2 72.1%) and -0.636 (I2 
79.1%), respectively. Both Zung Self-Rating Depression Scale (Zung-d) 
and one of the HDRS samples showed improvement. In the remaining, 
depression levels worsened after surgery. 
(3) Long-term follow-up: meta-analysis was performed only on BDI data. 
Summary ES indicated very slight depression improvement: -0.222 (I2 
40.9%). Additionally, the Zung-d sample showed improvement and the 
remaining Hospital Anxiety and Depression Scale – depression part 
(HAD-d) sample worsened. 
ii) GPi-DBS (figure 3): 
(1) Short-term follow-up: meta-analysis was conducted for BDI data and 
summary ES revealed depression improvement, despite heterogeneity 
was high (summary ES=-3.101, I2 57.9%). The remaining groups showed 
improvement as well. 
(2) Mid-term follow-up: depression, as assessed by the several instruments, 
improved in all the samples. 
b) STN versus comparator (figure 4):  
i) MT group: 
(1) Short-term follow-up: two samples (assessed with MADRS and Zung-d) 
showed a trend towards medical treatment superiority. The remaining 
five favored STN-DBS. 
(2) Mid-term follow-up: both groups favored STN-DBS. 
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ii) EFS group: 
(1) Short-term follow-up: in this single MADRS sample, medical treatment 
was superior. 
(2) Mid-term follow-up: two samples (BDI and MADRS) slightly favored 
STN-DBS. The remaining three samples (from HAD-d and also BDI and 
MADRS groups) pointed to medical treatment superiority, a tendency 
that is stronger in HAD-d sample. 
iii) GPi group: 
(1) Short-term follow-up: one BDI sample favored STN and the other one, 
along with the HDRS sample, favored GPi-DBS. 
(2) Mid-term follow-up: both BDI samples showed GPi-DBS superiority. 
Conversely, in the HDRS sample, STN-DBS was superior. 
 
2) Anxiety 
a) Pre – postop variation: 
i) STN-DBS (figure 5): 
(1) Short-term follow-up: one single sample from State and Trait Anxiety 
Inventory – Trait part (STAI-t) group revealed anxiety worsening 
following STN-DBS, with all the remaining studies showing 
improvement after the intervention. 
(2) Mid-term follow-up: meta-analysis was performed on State and Trait 
Anxiety Inventory – State part (STAI-s) and STAI-t data. Summary ES 
demonstrated slight anxiety improvement in STAI-s group and moderate 
worsening in STAI-t group: -0.930 (I2 0%) and 1.595 (I2 64.2%), 
respectively. Hospital Anxiety and Depression Scale – Anxiety part 
(HAD-a) single sample showed worsening. The remaining samples 
presented anxiety improvement. 
(3) Long-term follow-up: STAI-t single sample showed no change. 
Additionally, one sample assessed by HAD-a worsened and the 
remaining two (STAI-s and Zung-a groups) improved. 
ii) GPi-DBS (figure 3): 
(1) Short-term follow-up: the only existing sample performed Beck Anxiety 
Inventory (BAI) and anxiety seemed to improve. 
(2) Mid-term follow-up: the only existing sample performed STAI-s and 
STAI-t and both improved. 
b) STN versus comparator (figure 4): 
i) MT group: 
(1) Short-term follow-up: the single BAI sample results favored STN-DBS. 
The remaining groups apparently showed medical treatment superiority. 
ii) EFS group: 
(1) Short-term follow-up: the only existing sample performed Association 
for Methodology and Documentation in Psychiatry – Anxiety part 
(AMDP-AT) and the results favored STN-DBS. 
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(2) Mid-term follow up: one sample from STAI-s group favored medical 
treatment. The remaining two samples (from HAD-a and STAI-t groups) 
pointed towards STN-DBS superiority. 
iii) GPi group: 
(1) Mid-term follow-up: the only existing sample revealed GPi-DBS 
superiority, as assessed by the STAI-s and STAI-t. 
 
 
Discussion: 
Overall, objectively assessed depression and anxiety apparently improve after DBS, 
with effects being more pronounced in the short-term, and becoming weaker when 
follow-up is longer. Nonetheless, results are highly heterogeneous, both across studies 
and psychometric instruments. Concerning depression, STN-DBS shows superiority 
against medical treatment, but not when compared to eligible for surgery control 
groups, especially in the short-term. The opposite occurs for anxiety, as results favor 
medical treatment over STN-DBS, and STN-DBS when compared with eligible for 
surgery control group. Superiority of one target over the other is not evident from the 
results, due to significant heterogeneity of findings and paucity of studies, but data 
slightly favors GPi for both outcomes. 
Among the included comparison studies, two clinical trials on STN-DBS versus MT 
and STN-DBS versus GPi-DBS were found.  Witt and coworkers10 conducted a 
randomized multicenter clinical trial comparing best medical treatment (BMT) and 
bilateral STN-DBS, with depression and anxiety assessments as specific secondary 
outcomes. They concluded in favor of DBS safety at short-term follow-up (6 months), 
in carefully selected patients. The authors adopted “major psychiatric illness—such as a 
history of or current psychosis or a history of or current severe depression diagnosed by 
a psychiatrist” as exclusion criteria. A recent randomized multicenter clinical trial 
compared STN-DBS and GPi-DBS25, and the authors found a modest difference 
between the two groups favoring GPi-DBS with regard to depression. The results from 
both randomized studies conform to our general findings. 
The present work focused on depression and anxiety following bilateral DBS in PD, 
objectively assessed by psychometric instruments. In many of the excluded references, 
information was reported on DBS side effects (including psychiatric), without a 
standard definition of the clinical outcomes (concepts such as "slight disturbance of 
humor" or "mild depression" without further specification are hardly comparable). 
Additionally, this type of result contains no reference to the potential amelioration of 
any preoperative mild depressive symptoms following DBS. Therefore, in the present 
systematic review, the evaluation of the overall depression and anxiety levels following 
DBS was intended. 
One might wonder about possible bias related to dropouts by suicide, since 
postoperative outcomes would then be wrongly estimated10,24,25,29,31,61. However, a large 
multicenter study87 found that the completed suicide rate following subthalamic DBS in 
PD is less than 0.5%, suggesting that any suicide occurrences are unlikely to influence 
data in this regard. 
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We found that there are no long-term studies comparing the several therapeutic 
strategies for PD that adequately report objective data concerning anxiety and 
depression. Moreover, no long-term studies approaching this issue in GPi-DBS were 
found, and even short- and mid-term information regarding this target relies only in a 
few published studies. Therefore, there is a clear imbalance between the number of 
studies published in STN or GPi reporting objective psychometric data, thus limiting the 
strength of any comparative analysis. Measuring the outcome of either target could be 
important, since it has been suggested that patients undergoing either STN-DBS or GPi-
DBS might fare differently with regard to mood following surgery25. This could be 
important in order to tailor the procedure (i.e. target choice) for each patient, 
considering the individual profile of psychiatric symptoms. 
The conclusions of the present systematic review are naturally limited by the small 
amount and specificities of the available publications, namely taking into account that 
most of the investigations do not have a comparator, and the heterogeneity of methods 
and presentation of the findings. Another issue identified by this systematic review is 
the wide range of psychometric instruments used in the setting of DBS in PD, with a 
total of 11 scales for depression and 10 for anxiety, considering those with quantitative 
and comparable results only. Thorough analysis of available psychometric instruments 
might contribute to the rationalization of the choice of scales to use, by narrowing the 
number of options. For example Williams and collaborators have recently studied 9 
depression assessment scales and concluded that any of those is valid, provided that PD-
specific cutoff values are used. Anyway, the authors concluded that the 30-item 
Geriatric Depression Scale could be the most sensible choice in PD88. 
In summary, no definitive conclusions can be drawn from this meta-analysis, with the 
possible exception that the available data suggests that depression improves following 
STN-DBS at short-term, although heterogeneity of published results is significant. Our 
findings are consistent with the notion that DBS is a safe procedure with regard to 
depression and anxiety, regardless of the target chosen. It seems clear that organized 
scientific efforts should be carried out in order to reach consensus and issue 
recommendations on the use of a small number of validated scales that would allow 
proper assessment and reporting of data concerning depression and anxiety following 
DBS in PD. 
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Figures legends: 
 
Figure 1. Beck Depression Inventory forest-plot (STN-DBS). Beck Depression 
Inventory results following subthalamic stimulation (STN-DBS) with data grouped and 
analyzed by follow-up time periods. Effect size and 95% confidence interval are 
presented for each sample. Overall measure is presented for each time period.  
Abbreviations: country abbreviations according to ISO 3166-1 decoding table. 
 
Figure 2. Depression psychometric scales forest-plot (STN-DBS). Depression 
assessment results following subthalamic stimulation (STN-DBS) with data grouped 
and analyzed by psychometric instrument and sorted by ascending follow-up time. 
Effect size and 95% confidence interval are presented for each sample. 
Abbreviations: BRMES: Bech-Rafaelsen Melancholia Scale; BSId: Brief Symptom 
Inventory – depression part; GDS: Geriatric Depression Scale; HADd: Hospital Anxiety 
and Depression scale – depression part; HDRS: Hamilton Depression Rating Scale; 
MADRS: Mongomery-Åsberg Depression Rating Scale; POMSd: Profile Of Mood 
States – depression part; SCL90Rd: Symptom CheckList 90 Revised – depression part; 
UPDRS I,3: Unified Parkinson’s Disease Rating Scale, Part I, Item 3; Zungd: Zung self-
rating depression scale. Country abbreviations according to ISO 3166-1 decoding table. 
 
Figure 3. Pallidal stimulation outcomes forest-plot. Depression and anxiety assessment 
results following pallidal stimulation with data grouped and analyzed by psychometric 
instrument and sorted by ascending follow-up time. Effect size and 95% confidence 
interval are presented for each sample. 
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Abbreviations: BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; HDRS: 
Hamilton Depression Rating Scale; POMSd: Profile Of Mood States – depression part; 
STAIs: State and Trait Anxiety Inventory – state part; STAIt: State and Trait Anxiety 
Inventory – trait part. Country abbreviations according to ISO 3166-1 decoding table. 
 
Figure 4. Subthalamic stimulation versus comparators forest-plot. Depression and 
anxiety comparison results following subthalamic stimulation versus comparison 
groups. Data was grouped and analyzed by psychometric instrument and sorted by 
ascending follow-up time. Effect size and 95% confidence interval are presented for 
each sample. * Only postoperative evaluation. 
Abbreviations: AMDP-AT: Association for Methodology and Documentation in 
Psychiatry – anxiety part; BAI: Beck Anxiety Inventory; BDI: Beck Depression 
Inventory; BSIa: Brief Symptom Inventory – anxiety part; BSId: Brief Symptom 
Inventory – depression part; GDS: Geriatric Depression Scales; HDRS: Hamilton 
Depression Rating Scale; POMSd: Profile Of Mood States – depression part; STAIs: 
State and Trait Anxiety Inventory – state part; STAIt: State and Trait Anxiety Inventory 
– trait part; ES: Eligible for Surgery control group; BMT: Best Medical Treatment 
control group; GPi: Globus Pallidus internum comparison group. Country abbreviations 
according to ISO 3166-1 decoding table. 
 
Figure 5. Anxiety psychometric scales forest-plot (STN-DBS). Anxiety assessment 
results following subthalamic stimulation (STN-DBS) with data grouped and analyzed 
by psychometric instrument and sorted by ascending follow-up time. Effect size and 
95% confidence interval are presented for each sample. 
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Abbreviations: AMDP-AT: Association for Methodology and Documentation in 
Psychiatry – anxiety part; BAI: Beck Anxiety Inventory; BAS: Brief Scale for Anxiety; 
HADa: Hospital Anxiety and Depression scale – anxiety part; HAMA: Hamilton 
Anxiety scale; SCL90Ra: Symptom CheckList 90 Revised; STAIs: State and Trait 
Anxiety Inventory – state part; STAIt: State and Trait Anxiety Inventory – trait part; 
Zunga: Zung self-rating anxiety scale. Country abbreviations according to ISO 3166-1 
decoding table. 
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MANUSCRIPT SUBMISSION INFORMATION
Movement!Disorders is pleased to offer authors!web-based manuscript submission and peer-review
"#$$%&''()*(+,-.)/0%$)1,$/+2*)3('(4.5.
Authors are required to submit online at http://mc.manuscriptcentral.com/mds (http://mc.manuscriptcentral.com/mds). All
accompanying supplementary material (e.g., videos, appendices) should also be submitted online.
Policy Regarding Inappropriate Submissions and Publications
 
The editors, members of the editorial board, and publisher's staff at Movement Disorders take their responsibility seriously to assure that the
highest ethical publishing standards are maintained by assisting in safeguarding the medical scientific literature against fraudulent
publications. Please note manuscript submissions are now submitted for plagiarism detection through CrossCheck. Wiley-Blackwell policy is
based on the 'Guidelines on Good Publication Practice' published by the Committee on Publication Ethics (COPE) and can be found at Author
Services.  
 
Examples of fraud in scientific research include (but are not limited to):
 
1) The submission of duplicate publications using similar data (i.e., attesting that work submitted is original when, in fact, it was submitted to or
accepted by another journal);
 
2) Falsification of data, copyright, or information regarding conflict of interest;
 
3) Submission of work  from other sources that was not done by the author and is presented as a new and original  (plagiarism);  
 
4) Authorship (allowing one’s name to appear as an author or adding an author to a manuscript) without substantial input or without having
agreed to submission of the manuscript.
 
The above examples are not meant to be a comprehensive list of fraudulent publication practices. Rather, it should provide adequate basis for
careful consideration of avoidable conflicts and editorial scrutiny regarding inappropriate preparation and submission of manuscripts.
 
Manuscripts that have appeared in publications that are not peer-reviewed, are not registered in Pub Med, or are available only on the internet,
will be considered for publication in MDS as long as the Editor is informed and grants approval prior to submission of the manuscript for review.
If there are questions as to any issues regarding inappropriate submission, the Editor should be consulted prior to the submission. If a submitted
or published manuscript is discovered or suspected to be inappropriate, the authors will be asked for a written explanation. If the rationale
provided by the authors remains unsatisfactory in the judgment of the editors, the manuscript will be rejected or retracted. Retractions become a
matter of public record and are registered in Pub Med. The provost (or equivalent) of the authors' academic institutions will be informed of
inappropriate submissions or publications, and the authors will not be allowed to subsequently submit their research to MDS. The leadership of
MDS will also inform the editors and publishers of other journals which have published manuscripts judged to be inappropriately submitted to
MDS.
Editorial Office Information
Jose A. Obeso, MD, PhD!
University of Navarra
Pamplona, Spain
Phone: 34-948-194700, ext. 2038
E-mail:!movementdisorders.east@gmail.com!"(+02$3&678(391(1,$40.3/41/.*1+.$:;(+02*)3(5
C. Warren Olanow, MD, FRCPC
Mount Sinai School of Medicine
New York, New York, USA
Phone: 1-212-241-8435
E-mail:!cwolanow@gmail.com!"(+02$3&)<32+,3<:;(+02*)3(5
 
Submit your manuscripts online at!http://mc.manuscriptcentral.com/mds!"#$$%&''()*(+,-.)/0%$)1,$/+2*)3('(4.5. Please
note: Manuscripts submitted online are marked as received on the day of submission, evaluated by the Chief Editors, and assigned to associate
editors to oversee the review process. Papers that are not determined to be of sufficient clinical/scientific interest, focus, or relevance by at least
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two senior editors may be rejected without review. Through your individual Author Center on this website, you can view the status of your
manuscript as it progresses through the review process. Notification of the final disposition of each manuscript will be sent by E-mail to the
corresponding author on the day of decision. To submit your manuscript online:
 
Go to the!submission website!"#$$%&''()*(+,-.)/0%$)1,$/+2*)3('(4.5!"http://mc.manuscriptcentral.com/mds
"#$$%&''()*(+,-.)/0%$)1,$/+2*)3('(4.55
Click on the "Check for Existing Account" button at the bottom of the opening page.!If you do not already have an account, then create
one by clicking on the "Create an Account" button.!You will then be able to submit your manuscript.
Click on “Author Center.”!Follow the on-screen instructions carefully.!Tables and figures should be uploaded as individual files and not
part of the manuscript text.!(You do not need to mail hard copies of your manuscript).
At the end of a successful submission, you will see a confirmation screen with your manuscript number, and you will receive a separate
E-mail confirmation of manuscript reception by the journal.!If these two messages do not appear, then go into your Author Center and
make sure that you have clicked on the “Submit” button or contact technical support at
http://mchelp.manuscriptcentral.com/gethelpnow/question.htm
"#$$%&''()#12%*(+,-.)/0%$)1,$/+2*)3('61$#12%,37'8-1.$03,*#$(5.
 
Video Submission
File size limitations:!Files may be no larger than 50 MB.
General Information: When submitting manuscripts online, authors must indicate whether the article has an accompanying video. Video must be
submitted with manuscripts online in a digital format. If an article includes video, the upper right corner of the title page of the manuscript must
be marked “Video is part of ms.” Video clips should be limited to 90 seconds unless formal approval is obtained from the editorial office. Authors
must also supply, as part of the manuscript, a video legend for the video clip. If the author does not have the capacity to generate an electronic
video, the author may contact the editorial office for assistance.
Content:!Video content should be edited to illustrate the key findings in a concise and informative manner. They should be less than 90 seconds
in duration, except for special instances, which must be cleared in advance with the appropriate chief editor. Legends for the video segments
should be placed at the end of the article and should concisely and sequentially describe what is seen in the video so that it can be readily
understood by the viewer. Do not repeat explanatory material that is already in text. The video should be of high quality (both in content and
visibility). The video should be edited to ensure maximal efficiency and make the specific point; particularly, it should demonstrate the features
described in the text of the manuscript. In addition, the video should be labelled and should directly follow the sequence and content of the video
legend.
 
The use of text and/or special transition effects between the titles, subtitles and video
segments is permitted. The video you submit should be the final product that will be
published with the article. The Editors reserve the right to request additional video editing
by the authors (which may delay publication).
Patient Consent: The corresponding author must confirm in the author copyright form (Article V) that he or she has received a signed release
form from each patient videotaped authorizing the offline and/or online distribution of this video material. Manuscripts with videos will not be sent
out for review until the signed copyright form (Article V) with appropriate documentation is received.! The date of submission will be the date all
components of the article arrive at the editorial office.
For tips on preparing your video for submission, see the Technical Note by Jog and Grantier on digital video preparation.!This article appears in
volume 16, issue 6, and is available to all readers.
 
Cover Letter, Author Copyright Form, and Legal Information
Cover Letter. The cover letter should briefly describe the scientific or clinical importance of the manuscript. It must confirm that all authors have
read the manuscript, the paper has not been previously published, and it is not under simultaneous consideration by another journal. Also, a
statement that no ghost writing by anyone not named on the author list!!must be included (see Editorial in Movement Disorders 2005;20:1536).
Identify the corresponding author and provide a complete mailing address, telephone number, and email address for each author where
possible.
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Author Copyright Form. The author Copyright form includes (1) a statement on authorship responsibility, (2) a statement on financial disclosure,
(3) one of two statements on copyright or federal employment, and (4) a statement of acknowledgment. Each of the first three statements must
be read and signed by each co-author. The corresponding author must sign the acknowledgment statement (See the copyright form at the top
of this page).:5)!!When there is accompanying video or photographs on which patients can be identified, the corresponding author must sign the
video consent section (Article V).
 
Group Authorship. The journal does not limit the number of authors for an individual manuscript providing that: a)If there are multiple authors ,
all authors must meet the full criteria and requirements for authorship; b). If there is group, authorship, one or more individuals are designated
as authors or members of a writing group who meet full authorship criteria and who take responsibility for the group. Other members of the
group are not authors individually, but may be listed in the acknowledgment section (Flanagin A, Fontanarosa PB, DeAngelis CD. Authorship for
research groups. JAMA 2002;288:3166-3168).
 
Documentation of Author Roles. At the end of the manuscript, all authors must be listed, along with their specific roles in the project and
manuscript preparation. These should include but not be restricted to:
 
1.       Research project: A. Conception, B. Organization, C. Execution;
2.       Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
3.       Manuscript Preparation: A. Writing of the first draft, B. Review and Critique;
 
Data Access and Responsibility. For clinical trials sponsored by pharmaceutical companies, authors must state in their letter of submission that
(1) they have had full access to the data, (2) they have the right to publish all the data, and (3) they have had the right to obtain independent
statistical analyses of the data. For any report containing original data, at least one author should indicate that he or she “takes responsibility for
the integrity of the data and the accuracy of the data analysis” (DeAngelis CD, Fontanarosa PB, Flanagan A. Reporting financial conflicts of
interest and relationships between investigators and research sponsors. JAMA 2001;286:89-91).
 
Patient Consent. When submitting a patient video or photograph in which a patient can be identified, the corresponding author must provide the
Movement Disorders journal with a written confirmation (author copyright form, Article V) that stipulates that authorization signed by the patient
has been obtained in compliance with any laws regarding patient authorizations relating to the use or disclosure of protected health information
of the jurisdiction(s) to which the patient and the physician are subject including, if applicable, the United States Health Insurance Portability and
Accountability Act of 1996 (“HIPAA”).1 Manuscripts including, without limitation, a patient video or photograph will not be reviewed until a signed
author's accompanying statement (see Item V) has been received.
 
Copyright. The Movement Disorder Society will hold copyright to all published articles and videos. 
 
The copyright transfer agreement form can be downloaded from the top of this page. If you are a government employee, please check the
“Government-Owned Work” checkbox.
 
Financial Disclosures. All submissions require two entries that cover financial disclosure of all authors:
§ Financial disclosure related to research covered in this article: A statement that documents all funding sources and potential conflicts of
interest from each author that relate to the research covered in the article submitted must be included on the title page, regardless of
date. This material will be printed with the published article.
§ Full financial disclosure for the previous 12 months: A statement that documents all funding sources, regardless of relationship to the
current research in the article, from each author must be attached to the article at the end of the manuscript on the last page. This
material will be posted on the journal website and may be printed at the Editors’ discretion.
 
The copyright form that is signed by each author confirms that both of these entries are documented in the submitted material.
Expedited Publications (Fast Track)
Movement!Disorders will attempt to accommodate authors of manuscripts dealing with extremely topical issues or with findings of great
scientific or clinical importance by offering Expedited Review and Publication. Expedited papers will be rapidly reviewed and published within 8
weeks.
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Scope
Movement!Disorders publishes Full-length Articles, Reviews, Opinion papers/Viewpoints/Hypotheses/Editorials, Brief Reports, and Letters.
Case reports in which a definitive pathological or genetic diagnosis has been made can be submitted for publication in the Clinico-Pathological
Grand Rounds section of the journal. If the editor determines that the report is appropriate for the Clinico-Pathological Grand Rounds format two
referees can be solicited to discuss the case and become co-authors of the report. All articles in Movement Disorders, including letters, can be
accompanied by a video when appropriate.
Authors who are not perfectly fluent in English should have their manuscript professionally edited before submission. A list of independent
suppliers of editing services can be found at!www.blackwellpublishing.com/bauthor/english_language.asp
"#$$%&''((()*+,-.(/++%0*+12#134)-56'*,0$#57'/34+12#8+,340,4/),2%9.!:,%,3/2/!,0$#572!-,3!,+25!;13<!,!+12$!5;!+5-,+
=34+12#!16%75>/6/3$!2/7>1-/2!,$!http://www.wiley.co.jp/journals/editcontribute.html
"#$$%&''((()(1+/?)-5)@%'@5073,+2'/<1$-53$71*0$/)#$6+9.!All services must be arranged and paid for by the author, and use of one
of these services does not guarantee acceptance for publication. In addition, the journal will edit accepted papers to ensure uniformity of
language and style.
Full-Length Articles:!Full-length articles should present new clinical or scientific data in a field related to movement disorders. The
format should include - Structured Abstract!!(up to 250 words with only essential abbreviations (e.g. DNA)). Text; (up to 3000 words
exclusive of abstract, legends, and references) Minimize abbreviations. Tables and/or figures – up to 5.. Legends; should be concise and
describe results without repeating data in text. Videos; see above. The word count must appear on the title page.
Reviews:!Clinical and basic science Reviews are generally published upon request or after agreement with the editors of Movement
Disorders. Unsolicited Reviews will also be considered for publication. Reviews can be up to 3600 words. The word count must appear
on the title page.
Viewpoints, Hypotheses, Editorials: Editorials are solicited by the editors. Hypotheses and viewpoints!related to any aspect of
movement disorders may be submitted without solicitation. Viewpoints, Hypotheses/Editorials should be limited to 2000 words and 50
references. The word count must appear on the title page.
Brief Reports:!Brief reports are short original clinical or basic science reports related to any aspect of movement disorders. Structured
Abstracts up to 150 words, text up to 1500 words, tables and figures up to 2. References should be limited to 40. The word count must
appear on the title page.
Case reports!are not normally recommended for consideration as a research article or brief report and should be submitted as a letter
unless they make a scientifically important point.
Letters:!Letters to the Editors should have no more than five authors.  Movement disorders permits publication of two types of letters to
the editor with no abstract:
A)!Letters related to new observations. This section is appropriate for preliminary scientific observations and case presentations
that raise a novel clinical or scientific issue. Letters on new observations may be up to 500 words and contain no more than 1
table/figure and 7 references.
B)!A letter related to published articles. These may be submitted up to 8 weeks after the paper was published in print. Text length
for both letters and replies may be up to 500 words and contain 1 table/figure and up to 5 references. Letters from original authors
must be submitted within 4 weeks after request for response.
Articles reporting Clinical Trials:!Clinical Trial Reports must be written in accordance with the Consolidated Standards of Reporting
Trials (CONSORT) statement (Moher D et al., JAMA 2001;285:1987–1991; see also Moher D et al., Lancet 2001;357:1191–1194).
Authors should ensure that information on all of the critical design features listed in the CONSORT checklist is reported in the
manuscript. A CONSORT flow diagram should be included with the manuscript, clearly outlining the flow of patients through the trial. In
addition, a statement is required in the cover letter specifically confirming that there has been no ghost writing by anyone not named on
the author list (see Editorial in Movement Disorders 2005;20:1536). The precise financial relationship between a clinical trial sponsor and
the authors must be delineated in the manuscript.
13/02/27 15:34Movement Disorders - Author Guidelines - Wiley Online Library
Página 6 de 9http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-8257/homepage/ForAuthors.html
Medical Images –Medical Images should have no more than three authors. High quality clinical or scientific photographs, drawings,
scans, or other images may be submitted along with a title and a legend that describes what is observed in the image and its clinical,
scientific or conceptual significance. One image (could have multiple parts) in color or in black and white may be submitted. The image
may be based on an MRI, PET, pathologic specimen or clinical phenomenon, etc. Appropriate consent must be included. 200 words of
text are permitted as a legend. The legend should begin with a description of what is in the image and then can go on to describe the
clinical or pathologic circumstances relevant to the image. This is an imaging section and while we do want some clinical or pathological
detail as appropriate, the focus of this section is on the image. 
A New Section for Movement Disorders – Most movement disorder specialists were
initially attracted to the field by their experience with patients. With all of the advances
that have been made in the basic sciences and treatment, clinical phenomenology and
accurate diagnosis remain at the heart of the field. Starting with this issue of the
journal, we will inaugurate a new section entitled “Clinical Vignettes”, under the
direction of Dr. Steven Frucht. Each month we will feature one or two interesting cases
that illustrate an important diagnostic, clinical or therapeutic point. These cases may
illustrate novel clinical or scientific findings, but could also represent an unusual or
informative case. In most instances this will include a video demonstration of the
movement disorder. Clinical Vignettes should have no more than five authors. Each
case can be accompanied by one figure illustrating a salient feature of the vignette (an
image or pathologic slide, for example). Additional information can be added as
supplementary material on the web site. Clinical vignettes will frequently be
accompanied by a brief editorial commentary. Each case will be limited to 1000 words
of text; no abstract; and 10 references.   Submissions to this section should be labeled
“Clinical Vignettes”. They will be published in the regular print issue and will also be
available online. Any questions should be directed to Dr. Steven Frucht at
steven.frucht@mssm.edu (mailto:steven.frucht@mssm.edu), or to the journal staff.
Form of Manuscripts.
The text of the manuscript should be in the following sequence: (1) Title page, (2) Abstract, (3) Introduction, (4) Methods, (5) Results, (6)
Discussion, (7) Acknowledgment, (8) Authors' Roles, (9) Financial Disclosures of all authors (for the preceding 12 months), (10) References,
(11) Video Legend, (12) Figures, and (13) Tables. Pages should be numbered in succession, the title page being number one.
Title: Titles should be short, specific, and clear. They should not exceed 100 characters. Do not use abbreviations/acronyms in the title.
Title Page:The opening page of each manuscript should include: (1) article title (no abbreviations/acronyms); (2) authors' names and affiliations
(indicate the specific affiliation of each author by superscript, Arabic numerals); (3) name, address, telephone and email address of the
corresponding author; (4) word count; (5) a running title not exceeding 45 letters and spaces; (6) Key words – up to 5; (7) Financial
Disclosure/Conflict of Interest concerning the research related to the manuscript: All information on support and financial issues from all authors
relative to the research covered in the submitted manuscript must be disclosed regardless of date. Other financial information unrelated to the
current research covering the past year will be documented at the end of the manuscript (see below). (8) Funding sources for study.
Structured!Abstract:!We require that authors submit structured abstracts, but will consider unstructured abstracts if requested by the authors
prior to submission. The page following the title page of Full-Length Articles, and Reviews, should include an abstract of up to 250 words. The
abstract should be structured (background, methods, results, and conclusions) unless not appropriate for a specific article. The page following
the title page of a Brief Report,!!should include a structured abstract of up to 150 words. Authors are required to spell out all
abbreviations/acronyms in the structured abstract unless this has become accepted in the standard scientific literature (e,g, DNA, MPTP).
Introduction: Give a brief description of the background and relevance of the scientific contribution.
Methods: Describe the methodology of the study.!For experimental investigation of human or animal subjects, please state in this section that
an appropriate institutional review board approved the project. For those investigators who do not have formal ethics review committees, the
principles outlined in the “Declaration of Helsinki” should be followed. For investigations in human subjects, state in this section the manner in
which informed consent was obtained from the subjects. A letter of consent must accompany all photographs, patient descriptions, and
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pedigrees in which a possibility of identification exists. The authors are responsible for ensuring anonymity.
Results: No specific regulations.
Discussion: No specific regulations.
Acknowledgment: No specific regulations. These may be published on line at the discretion of the editor.
Author Roles: List all authors along with their specific roles in the project and preparation of the manuscript. These may include but are not
restricted to: 1) Research project: A. Conception, B. Organization, C. Execution; 2) Statistical Analysis: A. Design, B. Execution, C. Review and
Critique; 3) Manuscript: A. Writing of the first draft, B. Review and Critique.
Full Financial Disclosures of all Authors for the Past Year: Information concerning all sources of financial support and funding for the
preceding twelve months, regardless of relationship to current manuscript, must be submitted with the following categories suggested. List
sources or “none”.
 
Stock Ownership in medically-related fields Intellectual Property Rights
Consultancies Expert Testimony
Advisory Boards Employment
Partnerships Contracts
Honoraria Royalties
Grants Other
 
References: See “Details of Style” below for the proper formatting of citations and References.
Video Legend: No specific regulations but should be concise and reflect the sequence of observations on the video
Tables and Figure Legends: Double-space legends of fewer than 40 words for tables and figures. For photomicrographs, include the type of
specimen, original magnification, and stain type. Include internal scale-markers on photomicrographs when appropriate. Where applicable,
indicate the method used to digitally enhance images.
Tables: Tables!should be typed neatly, each on a separate page, with a title above and any notes below. Explain all abbreviations. Do not
repeat the same information in tables and figures that is present in text.Tables and figures should be uploaded as individual files and not part of
the manuscript text.!(You do not need to mail hard copies of your manuscript).!!
Figures and Illustrations: Adapt any figures to an appropriate size of art and letters to make them readable in the printed version. Illustrations
in full color are accepted at additional charge from the publisher. In the case of review articles or in special circumstances, color articles may be
included at no charge with the permission of the Chief Editor. Any illustration or figure from another publication must be acknowledged in the
figure legend, and the copyright holder’s written permission to reprint in print and online edition of Movement Disorders must be submitted to the
editors. In addition, figures to illustrate concepts are welcome particularly in review articles, and may be enhanced by a professional artists at no
cost to author at the discretion of the Editors.
Copyright and Disclosure Forms!The corresponding author should upload one PDF file that includes copyright and disclosure forms for all
authors to the Movement Disorders submission site with the revised version of the paper. These forms also can be emailed to
mdjedoffice@movementdisorders.org.!"#$%&'()#*+,*(--%.,/#(0,#,1'*%2(3*,324(356
Digital Artwork Preparation
For best reproduction, electronic artwork files must be in TIFF or EPS format, at a resolution of 600 dpi or higher, sized to print. Movement
Disorders offers!Rapid Inspector!"7''8)993$8%*%128,.'(34.$*#:24.(#9;$8%*<128,.'(39=>%9%1*,?4+286™ to help ensure that your
electronic graphics files are suitable for print purposes. This free, stand-alone software application will help you to inspect and verify illustrations
right on your computer. Go tohttp://rapidinspector.cadmus.com/wi/index.jsp
"7''8)993$8%*%128,.'(34.$*#:24.(#9;$8%*<128,.'(39=>%9%1*,?4+286!and create a new account.
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Details of Style
No patient identifiers (e.g., patient initials) are to be included in the manuscript or video (e.g., case reports, tables, figures, etc.).
Units of measure: Conventional units of measure according to the Systeme International (SI) are preferred. The metric system is preferred for
length, area, mass, and volume. Express temperature in degrees Celsius.
Drug Names: Use generic names only in referring to drugs, followed in parentheses after first mention by any commonly used generic variant.
Abbreviations: Follow the list of abbreviations given in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (see section
on References). For additional abbreviations, consult the CBE Style Manual (available from the Council of Biology Editors, 9650 Rockville Pike,
Bethesda, Maryland 20814, USA) or other standard sources. We encourage authors to minimize the use of abbreviations except where they are
routinely employed and the full term would be cumbersome (eg MPTP).
Spelling: American spelling is used throughout the Journal.
References
Movement!Disorders complies with the reference style given in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals". (See
Annals of Internal Medicine 1982;96:766-771, or British Medical Journal 1982:284:1766-1770.)
References are to be cited in the text by number, and in the list of References they are to be numbered in the order in which they are cited. The
reference section should be double-spaced at the end of the text, following the sample formats given below. Provide all authors' names when
fewer than seven; when seven or more, list the first three and add et al. Provide article titles and inclusive pages. Accuracy of reference data is
the responsibility of the author. For abbreviations of journal names, refer to List of Journals Indexed in Index Medicus (available from the
Superintendent of Documents, U.S. Government Printing Office, Washington DC 20402, USA, DHEW Publication No. (NIH) 83-267; ISSN 0093-
3821).
Sample References
"        !Journal article:
1. Krack P, Benzzzouz A, Pollak P, et al. Treatment of tremor in Parkinson’s disease by Subthalamic nucleus stiumulation. Mov Disord 1998;
13: 907-914.
"        !Book:
2.Fahn S, Jankovic J, editors.!Principles and Practice of Movement Disorders, Philadelphia, Churchill Livingstone, 2010, pp 96.
"        !Chapter in a book:
3. Olanow CW. Hpyerkinetic Movement Disorders. In: Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson JL, Loscalzo J. Eds.
Harrison’s Textbook of Medicine 17th edition. 2008; p2560-2565.!!!!!!!!
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Appendices: 
 
Appendix 1. Systematic review flow-chart 
 
 
 
 
Systematic review approach is outlined with respective proportion of excluded 
references attributed to each criterion. Literature distribution by psychiatric outcome 
and surgical target is also presented. * The same reference might be contained in more 
than one group. 
Abbreviations: PD: Parkinson’s Disease; DBS: Deep Brain Stimulation; STN: 
SubThalamic Nucleus; GPi: Globus Pallidus internum; STN + GPI: studies with data 
not discriminated regarding both targets; STN vs GPi: studies with comparison between 
both targets. 
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Appendix 2. Included references details 
 
 
 
Psychometric instruments used are highlighted with “x”. Stimulation target is marked 
with “!” in “STN” and/or “GPi” columns. Follow-up studies have “!” in the respective 
column and comparison studies are codified by 1 to 4 so different comparators can be 
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Alegret, 2004 (ES)  (a) x ! ! 6m, 1y
Altug, 2011 (TR)  (a,e) x x ! ! 3m, 6m
Auclair-Ouellet, 2011 (CA)  (a,l) x x ! ! 6m, 1y
Berney, 2002 (CH/CA)  (a,h) x x(d) ! ! 3-6m
Bordini, 2007 (US)  (a) x ! ! 6m
Daniele, 2003 (IT)  (a,e,F) x x ! ! 4m, 6m, 1y, 18m
De Gaspari, 2006 (IT)  (a) x ! ! 15m
Denheyer, 2009 (CA)  (a) x ! ! 16m
Derost, 2007 (FR)  (a,g,i) x ! ! 6m
Drapier, 2005 (FR)  (a) x ! ! 1y
Dujardin, 2004 (FR/CA/BE)  (a,A) x x ! ! 3m
Fasano, 2010 (IT)  (a) x x ! ! 8y
Funkiewiez, 2006 (FR/UK)  (a,i,o) x ! ! 3m
Gervais-Bernard, 2009 (FR)  (a) x ! ! 1y, 5y
Heo, 2008 (KR)  (a) x ! ! 6m, 1y
Houeto, 2002 (FR) x(J) x(c) x(J) x(c) ! ! 19m
Houeto, 2006 (FR)  (a) x x ! ! 6m, 2y
Huebl, 2011 (DE/UK)  (n) x ! ! 3m
Kaiser, 2008 (AT)  (a,e,h,D) x x x x x x ! ! 3m, 6m, 1y, 3y
Kalteis, 2006 (AT)  (a,e,D) x x x x x x x x ! ! 3w, 9w, 3m, 6m, 1y
Kishore, 2010 (IN)  (a,e) x x x ! ! 1y, 3y, 5y
Krack, 2003 (FR)  (a) x ! ! 1y, 3y, 5y
Krause, 2004 (DE)  (k) x ! ! 30m
Lhommée, 2012 (FR)  (a,j,I) x(c) x x(c) x(c) x x(c) ! ! 1y
Martínez-Martín, 2002 (ES)  (a) x x ! ! 6m
Merello, 2008 (AR)  (a) x ! ! 6m, 1y
Nazzaro, 2011 (US)  (c) x x ! ! 1y
Ory-Magne, 2007 (FR)  (a,e) x ! ! 1y, 2y
Perozzo, 2001 (IT)  (d) x x x ! ! 6m
Perriol, 2006 (FR)  (c) x ! ! 1y
Saint-Cyr, 2000 (US/CA)  (a,f) x ! ! 6m
Schadt, 2006 (US)  (a,h,m) x ! ! 23m
Schneider, 2010 (DE/US)  (a,e,f) x ! ! 5-10d, 18-24d, 3-4m
Schoenberg, 2008 (US)  (d) x x ! ! 5m
Simuni, 2002 (US)  (d) x ! ! 6m
Temel, 2007 (NL)  (b,g) x ! ! 3m, 1y
Tröster, 2003 (US)  (a) x ! ! 3,5m
Witjas, 2007 (FR)  (a) x ! ! 1y
Yamada, 2006 (JP)  (a,j) x ! ! 3m
Zibetti, 2007 (IT)  (a,e) x ! ! 1y, 2y
Zibetti, 2009 (IT)  (a,e,E) x x x ! ! 4m, 1y, 3y
Zibetti, 2011 (IT)  (a,e,E) x x x ! ! 1y, 5y, 9y
Morrison, 2004 (US)  (a,j) x ! ! 3m 2
Oyama, 2011 (JP)  (a,f,O) x ! ! 2-4w 2
Smeding, 2006 (NL)  (b) x x ! ! 6m 2
Wang, 2009 (CN)  (a,e,G,H) x(C) x ! ! 1w, 2m, 5m, 11m, 17m 2
Witt, 2008 (DE/AT)  (b,B) x x x ! ! 6m 2
York, 2008 (US)  (a) x x x x x ! ! 6m 2
Capecci, 2005 (IT)  (a,e) x ! ! 1y, 2y 3
Drapier, 2006 (FR)  (a,e) x x ! ! 3m, 6m 3
Péron, 2010 (FR/CH)  (a) x ! 35m 1,3
Montel, 2008 (FR)  (a) x x(c) ! 1y 2,3
Castelli, 2008 (IT)  (a) x x x ! 3y 3
McDonald, 2012 (US/UK)  (l) x x ! 1y 3
Fields, 1999 (US)  (n,M,N) x x x ! ! 3m
Ghika, 1998 (CH)  (d) x ! ! 3m
Loher, 2002 (CH/DE)  (q) x ! ! 3m, 1y
Burchiel, 1999 (US)* x ! ! ! 1y
Weaver, 2009 (US)* x ! ! ! 6m 2
Ardouin, 1999 (FR)  (a,g,K,L) x ! ! ! 3m, 6m 4
Follett, 2010 (US)  (a,m,p) x ! ! ! 2y 4
Rothlind, 2007 (US)  (a) x x x ! ! ! 15m 4
Volkmann, 2001 (DE)  (a) x ! ! ! 6m, 1y 4
Assessment Scales
Depression Anxiety
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distinguished. Grey shading denotes references excluded from analysis (non-
comparable data). 
 
Notes: 1 to 4 corresponds to comparators coding; 1: healthy control group, 2: medical 
treatment control group, 3 eligible for surgery control group and 4: GPi comparison 
group; * references with STN and GPi data not discriminated: no further analysis; (a) 
original data is pre M(SD) and post M(SD): changeM calculated as (postM - preM); 
changeSD calculated as ! [(preSD2 + posSD2 – 2 x r x preSD x posSD) / n]; (b) 
original data is pre M(SD) and change M(SD); (c) original data not 
quantitative/comparable (percentage of patients): no further analysis; (d) original data 
not quantitative/comparable (qualitative description): no further analysis; (e) within 
each period of time, the longest follow-up was selected for the analysis; (f) "x to y 
months" type follow-up: y months assumed; (g) original data reported by groups: 
separately considered for the analysis; (h) original data reported on total sample and by 
groups: total sample considered; (i) SD calculated from SE as (SE x !n); (j) original 
data reported in on and off state: only on considered; (k) original data not 
quantitative/comparable (no dispersion measure): no further analysis; (l) mean (SD) 
assumed; (m) SD calculated from 95% CI as [(upper limit - lower limit) / 3.92] x !n; (n) 
original data reported individually: preM(SD) and changeM(SD) calculated; (o) 
graphical data; (p) intention-to-treat analysis; (q) original data not 
quantitative/comparable (percentage of change): no further analysis; (A) cognitive 
outcomes compared with control group; depression and anxiety assessed only in 
patients; so, follow-up STN-DBS study design assumed; (B) "positive change scores 
indicate clinical improvement; data are (...) mean (SD) (...) for changes between 
baseline (before DBS) and 6 months": – changeM assumed; (C) HDRS not 
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consecutively assessed: "depression was evaluated (...) using the Self-Rating Depression 
Scale (...); every patient whose SDS score showed a mild depression, or more, was 
evaluated again (...) using the Hamilton Depression Scale"; (D) partial duplicates: BDI, 
POMSd, STAIs, STAIt, SCL-90-Rd and SCL-90-Ra data from Kaiser, 2008; BRMES 
and HAMA data from Kalteis, 2006; (E) partial duplicates: 3 years follow-up data from 
Zibetti, 2009; 9 years follow-up data from Zibetti, 2011 (and the respective preoperative 
data for each one); (F) data from n=20 (whole sample) and from n=9 (18 months follow 
up sample); evaluation moments at 3, 6, 12 and 18 months; n=20 preoperative data 
considered for short-term follow-up analysis; n=9 preoperative data considered for mid-
term follow-up analysis; (G) stimulation device was turned on 4 weeks after the 
surgery: postoperative moments converted to post-DBS moments by subtracting 1 
month; (H) "depression severity index" = "accumulative scores of each 
item"/"maximum scores of the scale": mean x 80 and SD x 80 assumed; (I) "the 
assessments took place (...) 12 months (...) later, with the exception of the cognitive 
status, which was controlled 3 months after surgery"; "outcome measures" = "motor 
function" + "cognitive status" + "psychiatric history" + "mood and behavioral 
modifications: ardouin scale" + "acute non-motor fluctuations": 1 year follow up 
assumed to mood evaluation; (J) results separated by groups "identical", "ameliorated" 
and "aggravated": not comparable with other studies; (K) Partial duplicate: 4 groups: 
STN versus GPI and Paris versus Grenoble: GPI in Grenoble, GPI versus STN 
comparison in Grenoble, STN in Paris, GPI in Paris and GPI versus STN comparison in 
Paris included; STN in Grenoble duplicated; (L) 4 groups: STN versus GPI and Paris 
versus Grenoble: only 57 in a total of 62 patients performed BDI assessment and the 
distribution by groups was not indicated: total n assumed for each group. (M) staged 
DBS; evaluation times were "1 month before first surgery, 2 months following first 
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surgery (unilateral), and 3 months following second surgery (bilateral)": 3 months 
follow-up assumed; (N) "Test-retest interval was about 3 months between baseline and 
post-unilateral electrode placement evaluation, and 4 months between post-unilateral 
and post-bilateral electrode placement evaluations. This occurred with the exception of 
one patient who on separate occasions had the lead and pulse generator repositioned 
following bilateral operation, resulting in a 22-month lapse between neuropsychological 
assessments after first and second DBS electrode placement.": global 3 months follow-
up assumed; (O) pre- and postoperative evaluations performed in patients group; only 1 
evaluation in control group: postoperative cross-sectional analysis assumed. 
Test-retest coefficient (r) was 0,66 for BAI79, 0,64 (short term) and 0,75 (mid- and long-
term) for BDI77, 0,79 for BSIa81, 0,84 for BSId81, 0,94 for GDS80, 0,98 for HADa84, 
0,99 for HADd84, 0,87 for HDRS75, 0,56 for MADRS76, 0,4 for STAIs86, 0,86 for 
STAIt86 and 0,651 for UPDRS I,382. 0,98 assumed for BRMES83. 0,75 assumed for 
POMSd85. Conservative value of 0,56 was assumed for SCL90Rd and Zungd. 
Conservative value of 0,4 was assumed for AMDP-AT, BAS, HAMA, SCL90Ra and 
Zunga. 
 
Abbreviations: in “follow-up” column, w, m and y refers to weeks, months and years, 
respectively; pre = preoperative data; post = postoperative data; M = mean; SD = 
standard deviation; SE = standard error; 95%CI = 95% confidence interval; r = test-
retest correlation coefficient; n=sample size; "change" refers to the postop - preop 
temporal change; AMDP-AT: association for methodology and documentation In 
psychiatry, anxiety part; Ardouina and Ardouind: “anxiety” and “depressive mood” 
items of the Ardouin scale, respectively; BAI: Beck anxiety inventory; BAS: brief scale 
for anxiety; BDI: Beck depression inventory; BRMES: Bech-Rafaelsen Melancholia 
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Scale; BSIa and BSId: anxiety and depression scales of the brief symptom inventory, 
respectively; COMP: comparison study; FU: follow-up study; GDS: geriatric depression 
scale; GPi: globus pallidus, pars interna; HADa and HADd: anxiety and depression 
parts of the hospital anxiety and depression scale, respectively; HAMA: Hamilton 
anxiety scale; HDRS: Hamilton depression rating scale; IOWAa and IOWAd: anxiety 
and depression parts of the IOWA scales of personality change, respectively; MADRS: 
Montgomery-Asberg depression rating scale; MINIa and MINId: “general 
anxiety”/”anxiety disorders” and “major depression episode/disorder” items of the 
“mini international neuropsychiatric interview, respectively; NMSQuesta and 
NMSQuestd: items “anxiety” and “feeling sad” of the non motor symptom 
questionnaire, respectively; POMSd: profile of mood states, depression domain; SCL-
90-Ra and SCL-90-Rd: anxiety and depression domains of the symptom checklist-90-
revised; STAIs and STAIt: state and trait (respectively) anxiety inventory; STN: 
subthalamic nucleus; UPDRS I,3: unified parkinson’s disease rating scale, part I, item 3 
“depression”; Zunga and Zungd: Zung self-rating anxiety and depression scales, 
respectively. Country abbreviations according to ISO 3166-1 decoding table.  
            
            
          
